Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis (Liposomal Cisplatin Formulation) in Patients With Advanced or Refractory Tumours
Phase of Trial: Phase I/II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Cisplatin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Proof of concept
- Acronyms LiPlaCis
- Sponsors LiPlasome Pharma; Oncology Venture
- 02 Aug 2017 Planned End Date changed from 1 Jun 2019 to 1 Jun 2018.
- 02 Aug 2017 Planned primary completion date changed from 1 May 2019 to 1 May 2018.
- 01 Aug 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History